Woman in a lab

Ofatumumab

Ofatumumab (also known as Arzerra) is an injection or infusion being developed for relapsing MS.

Phase 2 trials were completed by GlaxoSmithKline (GSK). Novartis have now purchased the rights to ofatumumab in order to carry out late stage trial.

Current phase of trial: Phase 3

Type of MS: Relapsing MS.

Find out more about ofatumumab